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The Cohort Consortium Vitamin D Pooling Project of Rarer Cancers (VDPP) brought together 10 cohorts to
conduct a prospective study of the association between vitamin D status, measured as serum concentrations of
25-hydroxyvitamin D (25(OH)D), and the development of 7 rarer cancer sites: endometrial, esophageal, gastric,
kidney, non-Hodgkin lymphoma, ovarian, and pancreatic cancers. The cohorts come from 3 continents, with
participants from a wide range of latitude who are racially diverse. Across each cancer site, there was no evidence
of a protective association between higher concentrations of 25-hydroxyvitamin D (>75 nmol/L) and cancer out-
come. An increased risk at very high levels ( 100 nmol/L) was noted for pancreatic cancer, conﬁrming previous
reports. The articles included in this issue detail the overall design and governance of the project, correlates of
vitamin D status, and results from the cancer site-speciﬁc investigations. The Vitamin D Pooling Project realizes
a major goal of consortium efforts, namely, to rigorously test hypotheses for rarer cancer outcomes that may not be
adequately addressed in any one prospective cohort study. The results of this study have application for the
planning and conduct of intervention trials, especially in determining potential risks.
case-control studies; neoplasms; prospective studies; vitamin D
Abbreviations: CI, conﬁdence interval; 25(OH)D, 25-hydroxyvitamin D; VDPP, Cohort Consortium Vitamin D Pooling Project of
Rarer Cancers.
Adequate vitamin D concentrations are necessary for
bone health and prevention of rickets. The widespread prev-
alence of low concentrations of vitamin D has triggered
great clinical, research, and public health interest in deter-
mining the amount of vitamin D required for optimal health.
The interest in vitamin D as a cancer preventive agent arises
from its biologic role in proliferation and apoptosis along
with the presence of vitamin D in most tissues.
The main source of circulating vitamin D is conversion of
7-dehydrocholesterol in the skin to cholecalciferol (D3)
upon exposure to ultraviolet B radiation (1). Dietary
sources, even with fortiﬁcation of food, remain a minor con-
tributor to vitamin D status. With the recognition of wide-
spread prevalence of deﬁcient or insufﬁcient vitamin D
concentrations, some have advocated increasing vitamin D
through supplements. In May 2009, a committee was ap-
pointed by the Food and Nutrition Board, Institute of Med-
icine of the National Academies, to evaluate and update the
dietary reference intake for vitamin D, as well as calcium
(2). The Committee is charged with evaluating evidence of
both the adequacy of current dietary vitamin D intake rec-
ommendations, including optimal dose and range of intake,
and the potential harms from excess intake.
In 2008, the evidence pertaining to vitamin D and its
association with cancer was reviewed by the International
Agency for Research on Cancer (3). As part of that review,
updated meta-analyses were conducted regarding the asso-
ciations between serum levels of 25-hydroxyvitamin D
(25(OH)D) and colorectal, breast, and prostate cancers.
The results showed a statistically signiﬁcant decrease in risk
of colorectal cancer per 1-ng/mL increase in serum
25(OH)D concentration among prospective studies (relative
risk ¼ 0.984, 95% conﬁdence interval (CI): 0.976, 0.991).
For prospective breast cancer studies, results were hetero-
geneous, and the decreased risk observed was not statisti-
cally signiﬁcant (relative risk ¼ 0.994, 95% CI: 0.964,
4 Am J Epidemiol 2010;172:4–91.024). No evidence for an association between 25(OH)D
and prostate cancer risk was observed (3). Published data for
other cancer sites were too sparse to conduct meta-analyses.
Since that review by the International Agency for Research
on Cancer, an additional prospective study of 25(OH)D
concentrations and pancreatic cancer was published (4).
Similar to the prior publication, an increased risk of pancre-
atic cancer was observed among individuals with the highest
levels, but there was no dose-response association (4).
This issue contains a series of articles from the Cohort
Consortium Vitamin D Pooling Project of Rarer Cancers
(VDPP), a collaborative effort involving 10 cohorts that
are members of the National Cancer Institute Cohort Con-
sortium. The VDPP was undertaken to address the gap in
knowledge of the association betweenvitamin D and cancer,
in particular the rarer cancers sites (3, 5). The VDPP, using
a central laboratory and standards provided by the National
Institute of Standards and Technology, examined the asso-
ciations between serum or plasma 25(OH)D concentrations,
the main circulating form of vitamin D, and the develop-
ment of 7 types of rarer cancer: endometrial, esophageal,
gastric, kidney, non-Hodgkin lymphoma, ovarian, and pan-
creatic cancers (6–11). The project was a nested case-
control study with the vast majority of samples assayed
speciﬁcally for this project. The reports include an overall
design paper, describing the governance of the consortium
and detailing the design and statistical approaches used in
the investigation, as well as a paper detailing the factors
correlated with vitamin D status. The results for each cancer
site are reported in separate papers except for gastric and
esophageal cancers, which were combined as upper gastro-
intestinal cancers.
The Cohort Consortium (http://epi.grants.cancer.gov/
Consortia/cohort.html) was established in 2000 to foster
large collaborative studies to investigate gene-gene and
gene-environment interactions with cancer. The ﬁrst 2 Con-
sortium projects focused on genetic studies of breast and
prostate cancer. The VDPP realizes a major goal and advan-
tage of the Cohort Consortium network, namely,the study of
rare cancer outcomes that no one cohort alone may be able
to examine. The VDPP brought together prospective cohort
studies with stored blood samples, diverse in ethnicity and
geographic distribution, to address the question of whether
vitamin D concentrations are associated with the develop-
ment of rarer cancer sites (Table 1). The cancer sites in-
vestigated were chosen because prior ecologic, preclinical
studies or observational studies suggested possible associa-
tions with vitamin D. In addition, the consortium prospec-
tive approach has advantages for cancer sites that present at
advanced stage at diagnosis and have high case-fatality
rates, such as esophageal, pancreatic, and ovarian cancers.
The considerable variation within and across cohorts in ra-
cial groups, latitude of residence, and vitamin D intake pro-
vided the opportunity to examine associations across a wide
range of clinically relevant concentrations of vitamin D,
measured as circulating 25(OH)D.
The overall design, description of the cohorts, and statis-
tical methodology are outlined in the methods paper (12). A
Table 1. Participating Cohorts in the Vitamin D Pooling Project of Rarer Cancers and Number of Cases per Cancer Site
Cohort and Location Population
Median Follow-up
Time, years (25th,
75th Percentile
of VDPP Cases)
No. of Cancer Cases Contributed by Cohort
Endometrial Kidney Lymphoma Ovarian Pancreatic
Upper GI
(Esophageal
and Gastric)
ATBC Study, Finland Smokers 8.7 (4.9, 12.7) 0 286 208 0 313 416
CPS-II, United States—
national
General 2.3 (1.3, 3.6) 51 58 135 27 65 40
CLUE, United States—
Washington County,
Maryland
General 10.1 (5.3, 14.7) 192 102 236 102 123 88
HPFS, United States—
national
Health
professionals
4.4 (2.6, 6.7) 0 0 133 0 0 0
MEC, United States—
Hawaii and California
General 2.1 (1.1, 3.3) 39 64 96 18 109 82
NYU-WHS, United
States—New York
Mammography
screening
10.8 (6.0, 14.6) 139 35 73 94 73 27
NHS, United States—
national
Registered
nurses
7.0 (4.0, 9.5) 163 0 145 127 0 0
PLCO (32, 33),
United States—national
General 4.5 (2.2, 6.8) 147 161 286 74 183 99
SMHS, China General 1.7 (0.9, 2.7) 0 32 8 0 27 131
SWHS, China General 4.7 (2.4, 6.6) 99 37 33 74 59 182
Total cancer cases 830 775 1,353 516 952 1,065
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention; CPS-II, Cancer Prevention Study II Nutrition Cohort; GI, gastro-
intestinal; HPFS, Health Professionals Follow-up Study; MEC, Multiethnic Cohort Study; NHS, Nurses’ Health Study; NYU-WHS, New York
University Women’s Health Study; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SMHS, Shanghai Men’s Health Study;
SWHS, Shanghai Women’s Health Study; VDPP, Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
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sayed in a central laboratory. A unique feature of the VDPP
was the availability of the ﬁrst serum standards for assays of
25(OH)D provided by the National Institute of Standards
and Technology. The hypothesis being tested was that
higher concentrations of vitamin D would be associated
with a lower risk of developing the cancers being
investigated.
The results of the VDPP do not suggest a beneﬁt from
higher concentrations of vitamin D, nor do they suggest an
increased risk from lower concentrations with respect to the
cancer sites studied (Figure 1). The observations from the
study of pancreatic cancer were consistent with prior reports
of an excess risk associated with concentrations of 25(OH)D
greater than 100 nmol/L (adjusted odds ratio ¼ 2.12, 95%
CI: 1.23, 3.64) (11). Because the previously reported studies
of 25(OH)D and pancreatic cancer also participated in the
VDPP, analyses were conducted excluding these cohorts. A
similar point estimate of risk was observed in association
with concentrations exceeding 100 nmol/L, although the
estimate was no longer statistically signiﬁcant (odds
ratio ¼ 2.23, 95% CI: 0.82, 6.08). Even in this large collab-
orative study, the numbers of cases and controls were lim-
ited at the extreme high end of the distribution, emphasizing
the challenge of studying both rare cancers and the associ-
ations with the extremes of exposures. These results, though
not conclusive, raise concern about recommendations for
use of high-dose supplementation with vitamin D that
may result in high serum concentrations of vitamin D.
The observation of a decreased risk of upper gastrointestinal
cancer with low concentrations of 25(OH)D among Asians
was also consistent with previously published studies
among Asian populations that observed a lower risk of can-
cer among individuals in the low range of vitamin D (7, 13,
14). Although data are sparse at the extremes of 25(OH)D
concentrations and in population subgroups, the consistency
with other reports in different populations makes it likely
that these results are not by chance. However, these results
should be conﬁrmed in other collaborative prospective
cohort projects.
As part of the project, an analysis of correlates of
25(OH)D was conducted to both guide analyses of site-
speciﬁc papers and to take advantage of the wide spectrum
of populations represented in the VDPP (15). Consistent
with other reports, individuals with higher 25(OH)D levels
tended to be male and to be lean, to engage in vigorous
physical activity, to have a greater dietary intake of vitamin
D, and to have greater use of multivitamin and calcium
supplements.
The current recommended daily intake according to the
Food and Nutrition Board of the Institute of Medicine,
National Academies, is age dependent and ranges from
200 to 600 IU, with the highest dose recommendations for
elderly women. The tolerable upper limit of intake, deﬁned
as the amount that is likely to pose no overall risk of adverse
effects, varies from 1,000 IU in infants to 2,000 IU in adults
(16). These recommendations are currently under review by
the Food and Nutrition Board (Institute of Medicine) and
may be altered. Finding the optimal dose of vitamin D is
important, as there appears to be risk at both extremes of the
distribution of vitamin D concentrations. Higher mortality
rates occur at the extreme low concentrations, as well as at
the high end of the distribution (3, 17). The VDPP suggests
a possible increased risk for pancreatic cancer at higher
vitamin D concentrations.
As the safety of high-dose supplementation for prolonged
periods is uncertain and reports of harm have surfaced at the
high end of 25(OH)D concentrations, caution should be
exercised in using high-dose supplementation in both clin-
ical practice and research settings. If high doses are to be
used, serum 25(OH)D concentrations should be monitored.
Clinically, high-dose supplementation may be recommen-
ded when measured vitamin D concentrations are very low.
Research studies may also use doses at the higher end of the
tolerable safe upper limit in order to maximize the ability
to detect effects. A search of the Clinical Trials Registry
maintained by the National Institutes of Health (http://
clinicaltrials.gov/), with vitamin D as the key term and lim-
itation to interventional studies, yielded 360 open studies.
Further search with key terms of ‘‘vitamin D and preven-
tion’’ and ‘‘vitamin D as an intervention’’ yielded 59 open
studies. The populations being studied included pregnant
women, children, and adults. Among those studies that
listed the dose of vitamin D, 28 studies had at least 1 in-
tervention arm with a vitamin D dose of 2,000 IU per day or
higher. For example, a weekly dose of 20,000 IU of vitamin
D (for an average daily dose exceeding 2,500 IU) is being
investigated in a 5-year intervention trial among individuals
with impaired glucose tolerance. A study with recruitment
beginning in January 2010 per the study website is the
Vitamin D and Omega-3 Trial (referred to as ‘‘VITAL’’),
which plans to recruit 20,000 individuals to test vitamin D
supplementation at a dose of 2,000 IU per day (http://
www.vitalstudy.org/). Participants are asked to limit their
supplement intake to no more than 800 IU per day for a po-
tential supplementation dose of 2,800 IU per day. As noted
previously, the safety of these doses, especially with pro-
longed supplementation of 1 year or more, is uncertain.
Given the current information on risks at extreme levels,
trial participants should have regular monitoring of blood
concentrations.
The predicted vitamin D levels have been suggested as
a surrogate for serum measures of 25(OH)D, but these may
not be sufﬁciently reliable for safety monitoring (3). The
Women’s Health Initiative observed a statistically signiﬁ-
cant but very modest correlation between reported diet
and supplement intake and measured 25(OH)D concentra-
tions (r ¼ 0.19; P < 0.001) (18). Indeed, only 3% of women
in the upper ﬁfth of the distribution (cutpoint, 67.6 nmol/L)
reported intakes greater than 1,000 IU per day. Among con-
trols in the VDPP, a similarly low correlation between total
vitamin D intake and serum levels was observed (r ¼ 0.26;
P < 0.0001). This relatively poor prediction of serum con-
centrations from reported diet and supplement intake em-
phasizes the need for clinical monitoring in practice and on
research studies. The need for monitoring may be particu-
larly critical for research participants with baseline pretrial
25(OH)D concentrations in the nondeﬁcient range. In the
VDPP study, increments of intake of 1,000 IU were associ-
ated with 18 nmol/L higher 25(OH)D. Therefore, an
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Figure 1. Odds ratios and 95% conﬁdence intervals for cancer risk by site across categories of circulating levels of 25-hydroxyvitamin D (nmol/L),
Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Odds ratios were derived from conditional logistic regression models. Reference
category:50–<75 nmol/L25(OH)D. A, kidneycanceradjustedfor education, bodymass index, height,smokingstatus at blooddraw, history of high
blood pressure at blood draw, history of diabetes at blood draw, and alcohol use at blood draw. B, non-Hodgkin lymphoma adjusted for height
( 165, >165–171, >171–177.781, >177.781 cm). C, upper gastrointestinal (combined esophageal and gastric) cancers adjusted for alcohol,
smoking, education, and history of gastric surgery. D, pancreatic cancer adjusted for body mass index (<18.5, 18.5–<25.0, 25.0–<30.0,
30.0–<35.0,  35.0 kg/m
2 (WHO categories), missing), smoking (never, former quit  15 years ago, former quit 1–<15 years ago, former
quit <1 year or currently smoking <20 cigarettes per day, and former quit <1 year or currently smoking  20 cigarettes per day), and diabetes
(yes, no, missing). The highest category of vitamin D and association with pancreatic cancer is statistically signiﬁcant (95% conﬁdence interval:
1.23, 3.64). E, endometrial cancer adjusted for education (less than high school, completed high school, vocational school, some college, college
graduate, graduate studies, missing), menopausal status (pre-, peri-, post-, missing), age at menarche (<13,  13 years of age, missing), parity (0,
1, 2, 3,  4, missing), oral contraceptive use (never, ever, missing), hormone replacement therapy (never, ever, missing), smoking (never, former,
current, missing), history of high blood pressure (yes, no, missing), history of diabetes (yes, no, missing), and body mass index (<25, 25–<30,  30
kg/m
2, missing). F, ovarian cancer adjusted for duration of oral contraceptive use and number of pregnancies. CI, conﬁdence interval; 25(OH)D,
25-hydroxyvitamin D; WHO, World Health Organization.
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(e.g., >75 nmol/L) who is taking more than 2,000 IU per
day of total vitamin D intake may have vitamin D concen-
trations in the range associated with increased risk of pan-
creatic cancer (11, 15).
The report from the International Agency for Research on
Cancer examining the association between vitamin D status
and cancer risk calls for randomized trials of vitamin D for
cancer prevention, stating that observational studies are un-
likely to ‘‘disentangle the complex relationships between
vitamin D and known cancer risk factors’’ (3, p. 1). The
report also points to contradictory results between observa-
tional studies and randomized trials as further evidence for
the need to conduct more trials rather than additional obser-
vational studies (3). However, observational studies exam-
ine a broad range of exposures and can evaluate multiple
health outcomes and potential harms, including rare out-
comes. Clinical trials are unlikely to be large enough or to
be conducted long enough to detect rare adverse events. In
the relatively short history of cancer chemoprevention, un-
warranted harms have occurred in intervention trials with
doses of supplements previously considered safe (19–21).
Cancer prevention trials require large sample sizes because
cancer outcomes are rare, even for the more common cancer
sites. As a consequence, many individuals are exposed, but
relatively few can derive the actual beneﬁt of a cancer pre-
vented, if the intervention does indeed decrease the risk of
cancer. Thus, under the principle of ‘‘ﬁrst do no harm’’ as
well as the wise expenditure of research dollars, it is critical
to have compelling evidence of potential beneﬁt for a pro-
posed preventive intervention that far outweighs harms, be-
fore embarking on large-scale trials. Observational studies
may provide such evidence, especially when outcomes are
rare. The results of the VDPP study should be included
in the overall evaluation of potential risks and beneﬁts of
vitamin D supplementation proposed for future trials or
being used in ongoing prevention trials.
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